Table 2. Characteristics of the treatment naïve and previously treated subgroup at teriflunomide treatment start.
| Total (n = 3239) | Treatment naive (n = 1824) | Previously treated (n = 1415) | p-value | |
|---|---|---|---|---|
| Sex, n (%) | 0.0107 | |||
| Male | 1120 (34.6) | 665 (36.5) | 455 (32.2) | |
| Female | 2119 (65.4) | 1159 (63.5) | 960 (67.8) | |
| Age at disease onset, median (IQR), mean (SD)* | 34.2 (26.6; 41.4) 34.5 (10.1) | 36.0 (28.1; 43.2) 36.1 (10.3) | 32.3 (25.5; 39.1) 32.6 (9.5) | <0.0001 |
| Age at TFL start, median (IQR), mean (SD)* | 42.9 (35.2; 50.1) 42.6 (10.7) | 41.4 (32.9; 48.7) 40.8 (10.8) | 44.9 (38.4; 51.8) 44.9 (10.1) | <0.0001 |
| Disease duration at TFL start, median (IQR), mean (SD)* | 5 (1; 12) 7.55 (8.13) | 1 (0; 5) 4.24 (6.58) | 10 (6; 17) 11.80 (7.96) | <0.0001 |
| Time since diagnosis, median (IQR), mean (SD)* | 1 (0; 7) 4.41 (6.34) | 0 (0; 0) 1.08 (3.63) | 7 (3; 13) 8.70 (6.50) | <0.0001 |
| Diagnosis, n (%) | <0.0001 | |||
| CIS | 215 (6.6) | 164 (9.0) | 51 (3.6) | |
| MS | 3024 (93.4) | 1660 (91.0) | 1364 (96.4) | |
| EDSS at TFL start, median (IQR), mean (SD) | 2.0 (1.0; 3.0) 2.13 (1.46) | 2.0 (1.0; 2.5) 1.95 (1.26) | 2.0 (1.5; 3.0) 2.35 (1.65) | <0.0001 |
|
ARR in year prior to TFL start, median (IQR), mean (SD) |
0 (0; 1) 0.53 (0.62) | 1 (0; 1) 0.79 (0.61) | 0 (0; 0) 0.19 (0.46) | <0.0001 |
| Number of relapses in year prior to TFL start, n (%) | <0.0001 | |||
| 0 | 1736 (53.6) | 552 (30.3) | 1184 (83.7) | |
| ≥1 | 1503 (46.4) | 1272 (69.7) | 231 (16.3) |
ARR: Annualized relapse rate, CIS: Clinically isolated syndrome, DMT: Disease-modifying therapy, EDSS: Expanded Disability Status Scale, IQR: Interquartile range, MS: Multiple sclerosis, n: Number, SD: Standard deviation, TLF: Teriflunomide.
*in years.